Cancer Therapy News and Research

RSS

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

30 Jun 2010

Renowned experts discuss new approaches to cancer therapy at international conference

An international conference attended by more than 70 of the world's leading experts and investigators in the field of Ephs and ephrins was held locally this week and hosted by Waldemar Debinski, M.D., Ph.D., director of the Brain Tumor Center of Excellence at Wake Forest University Baptist Medical Center.

30 Jun 2010

Mayo Clinic biostatistician become director of CALGB

In a move that will improve efficiency and collaboration in cancer research, Mayo biostatistician Daniel Sargent, Ph.D., will become director of the Statistical Center for the Cancer and Leukemia Group B (CALGB), a national association of cancer researchers funded primarily by the National Cancer Institute (NCI).

30 Jun 2010

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

Scientists have discovered that when they transplant ovaries from young mice into aging female mice, not only does the procedure make the mice fertile again, but also it rejuvenates their behaviour and increases their lifespan. The question now is: could ovarian transplants in women have the same effect?

29 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

29 Jun 2010

Millions of cancer survivors are parenting young children, says Wake Forest researcher

In the first ever published estimate of the percentage and number of cancer survivors who live with their minor children, a team led by a Wake Forest University Baptist Medical Center researcher found that millions of cancer survivors are parenting young children, highlighting a group of survivors with very special needs.

29 Jun 2010

APP to market Anastrozole 1 mg tablets in U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

29 Jun 2010

Lead researchers develop a novel technique to deliver cancer drugs

A new way to deliver cancer drugs using gas bubbles and sound waves is to be developed at the University of Leeds. The project will enable highly toxic drugs to be delivered in small doses directly to tumours, where their toxicity can safely be put to good use.

29 Jun 2010

MagForce's Nano-Cancer therapy receives European regulatory approval

Following two decades of intensive research and development efforts, MagForce Nanotechnologies AG, a Berlin-based medical technology company founded in 1997, has received European regulatory approval for its Nano-Cancer® therapy.

28 Jun 2010

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Cancer Research UK scientists have discovered certain ovarian tumour cells that are resistant to chemotherapy can survive a first round of treatment and go on to "re-grow" the cancer. This could help explain why the disease can be difficult to treat, according to new research published in Oncogene today (Monday).

28 Jun 2010

Poster presentation at MASCC Conference summarizes MuGard clinical experience

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.

28 Jun 2010

Experts to meet in Miami to discuss new ways of avoiding errors in radiation therapy

A meeting in Miami this week will bring together some of the world's leading experts from inside and outside the clinic to discuss safety in radiation therapy -- a critical method for treating cancer.

25 Jun 2010

Devastating 21% SGR cuts to Medicare disproportionately impact cancer care

Today a group of cancer patients, oncologists, oncology nurses and practice administrators will meet with Members of Congress to speak out about the enormous burden placed by the massive Medicare cuts to U.S. cancer care, and to offer solutions.

24 Jun 2010

UNC team provides first example of successful radiomitigation in mammals

While radiation has therapeutic uses, too much radiation is damaging to cells. The most important acute side effect of radiation poisoning is damage to the bone marrow. The bone marrow produces all the normal blood cells, and therefore a high dose of radiation can lead to low blood counts of red cells, platelets and white blood cells.

24 Jun 2010

Hoag Hospital launches IORT program for breast cancer treatment

Hoag Hospital announced the launch of its Intraoperative Radiation Therapy program as part of its progressive, comprehensive approach to breast cancer treatment. IORT is a radiation therapy technique in which a concentrated dose of radiation is delivered to a cancerous tumor site during surgery after the tumor is removed. Hoag Hospital is the first in Orange County to offer IORT brachytherapy for breast cancer as a component of a definitive treatment approach.

24 Jun 2010

New poll illustrates difficult situations cancer patients face in affording needed health care

A new poll illustrates the difficulty that cancer patients, survivors and their families face in affording needed health care and paying for other basic necessities such as food and heat, underscoring the need to strongly implement the Affordable Care Act so that it works for people with cancer.

24 Jun 2010

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

IsoRay, Inc. announced today that it has completed a license agreement with Hologic, Inc. for exclusive worldwide distribution rights to the GliaSite® radiation therapy system, the world's only FDA-cleared balloon catheter device used in the treatment of brain cancer. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

From Hologic, Inc. 23 Jun 2010

UK cancer survival rates increase at 3% each year

The number of people who are living with and beyond cancer (cancer survivors) has risen, according to new figures from the National Cancer Intelligence Network.

23 Jun 2010

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

Ensuring the optimum radiation dose on the same day as the brachytherapy implant in prostate cancer treatment manages to control the illness in about 95% of the cases. This is the result of research undertaken at the University Hospital of Navarre and published in the latest issue of Brachytherapy, journal of the American Society of Brachytherapy.

23 Jun 2010

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

ImmunoCellular Therapeutics, a clinical-stage biotechnology company focused on developing new immune-based products to treat cancer, today announced it has entered into an exclusive licensing agreement with Targepeutics, Inc. for ImmunoCellular's acquisition of Targepeutics' worldwide intellectual property rights surrounding the IL-13 receptor, alpha 2.

23 Jun 2010

Cancer Therapy News and Research

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Renowned experts discuss new approaches to cancer therapy at international conference

Mayo Clinic biostatistician become director of CALGB

Ovarian transplant procedure increases lifespan, restores fertility in aging mice

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Millions of cancer survivors are parenting young children, says Wake Forest researcher

APP to market Anastrozole 1 mg tablets in U.S.

Lead researchers develop a novel technique to deliver cancer drugs

MagForce's Nano-Cancer therapy receives European regulatory approval

Chemotherapy resistant ovarian tumour cells "re-grow" cancer

Poster presentation at MASCC Conference summarizes MuGard clinical experience

Experts to meet in Miami to discuss new ways of avoiding errors in radiation therapy

Devastating 21% SGR cuts to Medicare disproportionately impact cancer care

UNC team provides first example of successful radiomitigation in mammals

Hoag Hospital launches IORT program for breast cancer treatment

New poll illustrates difficult situations cancer patients face in affording needed health care

IsoRay, Hologic complete exclusive worldwide distribution agreement for GliaSite radiation therapy system

UK cancer survival rates increase at 3% each year

Optimum radiation dose on same day as brachytherapy implant can control prostate cancer

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Your guide to microplate readers for cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News